Renewed confi dence is placed in BioPhausia as main supplier of parallel-imported pharmaceuticals to

BioPhausia and Apoteksgruppen have renewed the cooperation agreement that was
signed in the spring of 2010. Under the agreement, BioPhausia will continue to
be Apoteksgruppen's main supplier of parallel-imported pharmaceuticals through
the Company's subsidiary Cross Pharma.

"I am delighted that Apoteksgruppen has reaffi rmed its confi dence in Cross
Pharma as the main supplier of parallel-imported pharmaceuticals," comments
BioPhausia's CEO Maris Hartmanis. "We are broadening Cross Pharma's product
offering in the coming year, and it is our hope that this will enhance our
cooperation with Apoteksgruppen."

In 2010, Parallel-imported products was BioPhausia's largest segment in terms of
sales, with a fi gure of SEK 252 million. These operations are conducted in
Cross Pharma, which is constantly renewing and expanding its product portfolio.
In December 2010, it was decided to further increase the number of licences,
thereby increasing the number of parallel-imported pharmaceuticals that can be
offered to pharmacy chains in Sweden. With a broader product offering, Cross
Pharma is now positioned for future growth.

Apoteksgruppen is a national chain of 150 pharmacies - from Gällivare in the
north to Borrby in the south - run by individual pharmacy owners under a common
service organisation. The combination of the large chain's economies of scale
and the local entrepreneurs' knowledge, service and customer focus creates
personal and inspiring pharmacies.

FOR FURTHER INFORMATION

Maris Hartmanis CEO, +46-8-407 64 30

maris.hartmanis@biophausia.se


[HUG#1495663]